Experience

OncoBeta - epidermal radioisotope therapy

• Germany
• Medical Equipment Manufacturing
• 1 - 100 Employee

• Business Development Consultant

  • Nov 2020 - Present

  Introduced and launched, to UK, novel medical device for non-melanoma skin cancers using Rhenium-188. This technology provides a painless, single session and non-invasive treatment for these common conditions. Introduced and launched, to UK, novel medical device for non-melanoma skin cancers using Rhenium-188. This technology provides a painless, single session and non-invasive treatment for these common conditions.


OncoSil Medical
• Australia
• Medical Equipment Manufacturing
• 1 - 100 Employee
• Senior Account Manager

  • Jan 2021 - Present

Tunstall Healthcare
• Netherlands
• Hospitals and Health Care
• 1 - 100 Employee
• Business Development Director

  • Mar 2020 - Oct 2020


BTG plc

• United States
• Medical Device
• 200 - 300 Employee

• Account Manager

  • Aug 2014 - Mar 2020

  Worked in the field of interventional oncology with innovative medical device therapies, including Cryo-ablation used in renal, prostate, lung and bone lesions as well as for cryo-analgesia and other niche applications. During a cryoablation procedure, extreme cold is delivered through very small needles, creating an iceball to destroy the targeted tissue. The physician monitors the ablation zone to ensure adequate treatment using direct visualization or image guidance such as ultrasound or computed tomography (CT). Additional focus was on developing selective internal radiation therapy (SIRT) for liver cancer at key centres. This loco-regional therapy has been used mainly in intermediate to advanced disease with good results though increasingly there is significant interest in its use in the curative setting with the aim of downstaging to resection or transplant, or as a bridging strategy for patients on the transplant list. (TheraSphere) Also worked on drug eluting beads for Trans Arterial Chemo Embolisation (TACE) for both HCC and metastatic liver cancer, including the launch of the first radio-opaque drug eluting bead. (DC Bead / DC Bead Lumi) Show less



Amersham Health / GE Healthcare

• Senior Account Manager & National Product Support Specialist

  • Apr 1993 - Aug 2014

  The first eleven years were with Amersham International / Amersham Health and from 2004 with GE after they acquired the business. During this 21 year career I managed a large portfolio of products used in many disease areas primarily in diagnostic / molecular imaging, nuclear medicine and radionuclide therapy. In the Amersham years this included sealed sources for therapy as well as cobalt-57 marker and QC sources. Involved in the launch of several new products, in nuclear cardiology, neurology & lung cancer imaging; as well as brachytherapy products. Consistently delivered above target sales. Uniquely grew one key brand to exceed £1.3 million territory sales from launch to end of 2011. Generated top line sales growth in all key brands and core products by developing partnership relationships with customers. Promoted key marketing campaigns to wide range of medical specialists, developing broad understanding of disease areas and impact of products. Organised regular meetings and symposia utilising expert speakers or by delivering clinical presentations personally to promote product range and educate audiences about their roles, and optimal use in clinical practice. Provided training support to newer team members, over several years in relation to: constructing tenders, understanding technical aspects of product portfolio and identifying the opportunities to grow the business. Managed significantly expanded territory over the three years to December 2011 delivering a further increase in sales growth of around £1.5 million, from total sales of £2.8 million in December 2008 to £4.4 million in December 2011 Show less



Centocor

• Biotechnology Research
• 400 - 500 Employee

• Monoclonal Antibody Specialist

  • Mar 1992 - Mar 1993

  Worked in the innovative biotechnology sector to launch and grow a therapeutic monoclonal antibody against endotoxin (Centoxin HA-1A) used in patients in critical care / ITU with bacteraemia, sepsis and septic shock. Mortality was shown to be reduced by 40% in gram negative infection. Anecdotal cases were described of young children with meningococcal sepsis who were not expected to live more than a few hours, who responded to this treatment and were back home within a week. Show less


Bayer
• Chemical Manufacturing
• 700 & Above Employee
• Hospital Sales Specialist

  • Apr 1988 - Mar 1992